Related Experiment Video

Updated: May 28, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

STRIP2 confers acquired resistance to EGFR-TKIs in lung adenocarcinoma by modulating IGF2BP3-dependent Twist1

Xilin Zhang1, Jing Gu2, Ziwei Lei3

  • 1Central Laboratory, Huzhou Key Laboratory of Translational Medicine, First Affiliated Hospital of Huzhou University, Huzhou, Zhejiang 313000, China.

Genomics
|May 26, 2026
PubMed
Abstract

Insights

The STRIP2-IGF2BP3-Twist1 axis drives acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in lung adenocarcinoma. Targeting this axis may overcome treatment resistance in patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Acquired resistance to EGFR-TKIs is a significant challenge in lung adenocarcinoma (LUAD) treatment.
  • Mechanisms underlying TKI resistance in LUAD are not fully understood.

Purpose of the Study:

  • To investigate the STRIP2-IGF2BP3 axis's role in EGFR-TKI resistance in LUAD.
  • To elucidate the mechanism of STRIP2-IGF2BP3 in regulating Twist1 stability and TKI sensitivity.
  • To assess the prognostic value of STRIP2, IGF2BP3, and Twist1 in LUAD.

Main Methods:

  • In vitro and in vivo experiments were conducted to assess the STRIP2-IGF2BP3 axis's impact on TKI sensitivity.
  • Investigated the molecular mechanism involving m6A modification and Twist1 stabilization.
  • Analyzed LUAD tissue samples for prognostic relevance of key markers.

Main Results:

  • STRIP2 expression was elevated in TKI-resistant LUAD samples and cells.
  • STRIP2 knockdown restored sensitivity to EGFR-TKIs.
  • The STRIP2-IGF2BP3 axis enhances acquired resistance by promoting m6A modification and stabilizing Twist1.

Conclusions:

  • The STRIP2-IGF2BP3-Twist1 axis is a key mediator of acquired resistance to EGFR-TKIs in LUAD.
  • This axis represents a promising therapeutic target for overcoming TKI resistance in LUAD patients.
Keywords:
Acquired resistanceInsulin-like growth factor II mRNA binding protein 3Lung adenocarcinomaStriatin interacting protein 2Twist1

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...